Farshad Sheikhesmaili1, Ali Jalili2, Elmira Taghizadeh1, Shohreh Fakhari2, Khashaiar Jalili3, Ebrahim Ghaderi4, Ezatollah Rahimi2. 1. Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences Sanandaj, Iran. 2. Cancer and Immunology Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences Sanandaj, Iran. 3. Faculty of Sciences, University of Waterloo Waterloo, Ontario, Canada. 4. Social Determinants of Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences Sanandaj, Iran.
Abstract
BACKGROUND: Inflammation and inflammatory mediators have been proposed to be key players in the pathobiology of Irritable bowel syndrome (IBS. The chemokine CCL28 plays a role in the trafficking of inflammatory cells into mucosal tissues. However, its levels in patients with IBS has not been yet elucidated. METHOD: In this study, the levels of CCL28 were measured in the serum of 41 patients with IBS and 41 age- and gender-matched normal individuals using Elisa. Then, the receiver operating characteristic (ROC) curve was conducted to assess the diagnostic value of CCL28. RESULTS: Our data showed that the levels of CCL28 are significantly elevated in patients with IBS compared to the control donors. Moreover, we observed that the level of CCL28 is associated with many clinical symptoms such as constipation, diarrhea, and abdominal pain. The area under the ROC curve was 0.71 (95% confidential interval, 0.598-0.823), the sensitivity and specificity of CCL28 for the diagnosis of IBS patients were 68.3% and 70.7%, respectively with a cut off of 278.9 ng/mL. CONCLUSIONS: We demonstrated that CCL28 is elevated in patients with IBS and correlates with clinical findings, indicating that CCL28 might be an appropriate biomarker for the diagnosis of IBS; however, further studies are necessary. AJCEI
BACKGROUND: Inflammation and inflammatory mediators have been proposed to be key players in the pathobiology of Irritable bowel syndrome (IBS. The chemokine CCL28 plays a role in the trafficking of inflammatory cells into mucosal tissues. However, its levels in patients with IBS has not been yet elucidated. METHOD: In this study, the levels of CCL28 were measured in the serum of 41 patients with IBS and 41 age- and gender-matched normal individuals using Elisa. Then, the receiver operating characteristic (ROC) curve was conducted to assess the diagnostic value of CCL28. RESULTS: Our data showed that the levels of CCL28 are significantly elevated in patients with IBS compared to the control donors. Moreover, we observed that the level of CCL28 is associated with many clinical symptoms such as constipation, diarrhea, and abdominal pain. The area under the ROC curve was 0.71 (95% confidential interval, 0.598-0.823), the sensitivity and specificity of CCL28 for the diagnosis of IBS patients were 68.3% and 70.7%, respectively with a cut off of 278.9 ng/mL. CONCLUSIONS: We demonstrated that CCL28 is elevated in patients with IBS and correlates with clinical findings, indicating that CCL28 might be an appropriate biomarker for the diagnosis of IBS; however, further studies are necessary. AJCEI
Authors: Vinton S Chadwick; Wangxue Chen; Dairu Shu; Barbara Paulus; Peter Bethwaite; Andy Tie; Ian Wilson Journal: Gastroenterology Date: 2002-06 Impact factor: 22.682
Authors: A Y Del Valle-Pinero; A C Martino; T J Taylor; B L Majors; N S Patel; M M Heitkemper; W A Henderson Journal: Neurogastroenterol Motil Date: 2011-09-23 Impact factor: 3.598
Authors: Nicolas Cenac; Christopher N Andrews; Marinella Holzhausen; Kevin Chapman; Graeme Cottrell; Patricia Andrade-Gordon; Martin Steinhoff; Giovanni Barbara; Paul Beck; Nigel W Bunnett; Keith A Sharkey; Jose Geraldo P Ferraz; Eldon Shaffer; Nathalie Vergnolle Journal: J Clin Invest Date: 2007-02-15 Impact factor: 14.808
Authors: Alice Miles; Evaggelia Liaskou; Bertus Eksteen; Patricia F Lalor; David H Adams Journal: Am J Physiol Gastrointest Liver Physiol Date: 2008-02-28 Impact factor: 4.052
Authors: John Macsharry; Liam O'Mahony; Aine Fanning; Emer Bairead; Graham Sherlock; Jay Tiesman; Andy Fulmer; Barry Kiely; Timothy G Dinan; Fergus Shanahan; Eamonn M M Quigley Journal: Scand J Gastroenterol Date: 2008 Impact factor: 2.423
Authors: Giovanni Barbara; Vincenzo Stanghellini; Roberto De Giorgio; Cesare Cremon; Graeme S Cottrell; Donatella Santini; Gianandrea Pasquinelli; Antonio M Morselli-Labate; Eileen F Grady; Nigel W Bunnett; Stephen M Collins; Roberto Corinaldesi Journal: Gastroenterology Date: 2004-03 Impact factor: 22.682
Authors: Sven H Loosen; Markus S Jördens; Mark Luedde; Dominik P Modest; Simon Labuhn; Tom Luedde; Karel Kostev; Christoph Roderburg Journal: J Clin Med Date: 2021-12-16 Impact factor: 4.241